Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma

Stefano Cavalieri(University of Milan), Ester Orlandi(Fondazione IRCCS Istituto Nazionale dei Tumori), Riccardo Villa(National Center for Oncological Hadrontherapy), Lisa Licitra(University of Milan), Sara Ronchi(National Center for Oncological Hadrontherapy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Viviana Vitolo(National Center for Oncological Hadrontherapy), Amelia Barcellini(University of Pavia), Barbara Vischioni(National Center for Oncological Hadrontherapy), Maria Bonora(National Center for Oncological Hadrontherapy)
Radiotherapy and Oncology
September 8, 2021
10.1016/j.radonc.2021.08.021
Cited by 17

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780